8-K: Cardinal Health Loses OptumRx Contract, Reaffirms Fiscal 2024 Guidance and Long-Term Targets

Cardinal Health announced the nonrenewal of its pharmaceutical distribution contracts with OptumRx, while reaffirming its fiscal 2024 non-GAAP EPS guidance and long-term financial targets.

Summary

• Cardinal Health's pharmaceutical distribution contracts with OptumRx will not be renewed when they expire at the end of June 2024.
• Despite this loss, the company has reaffirmed its fiscal 2024 non-GAAP diluted EPS guidance of $7.20 to $7.35.
• Cardinal Health also reiterated its long-term segment profit CAGR target of 4% to 6% and its consolidated non-GAAP EPS CAGR target of 12% to 14% for fiscal years 2024 to 2026, relative to a fiscal 2023 baseline.
• The company expects growth in fiscal 2025 in both Pharmaceutical and Specialty Solutions segment profit and non-GAAP diluted EPS, partially offsetting the OptumRx impact through new customer wins and specialty growth.
• Sales to OptumRx accounted for 16% of Cardinal Health's consolidated revenue in fiscal year 2023, with approximately 90% of these sales coming from the Pharmaceutical Distribution business.
• The company anticipates lower-than-average adjusted free cash flow in fiscal 2025 due to the unwinding of negative net working capital associated with the OptumRx contract and day-of-the-week timing, but still expects to generate approximately $2B on average from fiscal 2024 to 2026.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the loss of the OptumRx contract is a significant negative, the company's reaffirmation of its financial guidance and long-term targets, along with its plans to mitigate the impact, provide a sense of stability and confidence.

Positives

• Cardinal Health has reaffirmed its fiscal 2024 non-GAAP EPS guidance despite the loss of the OptumRx contract.
• The company has also reaffirmed its long-term growth targets for both segment profit and consolidated non-GAAP EPS.
• Cardinal Health expects to partially offset the impact of the OptumRx contract loss through new customer wins and growth in its specialty business.
• The company anticipates continued growth in fiscal 2025 in both Pharmaceutical and Specialty Solutions segment profit and non-GAAP diluted EPS.
• Cardinal Health expects to generate approximately $2B in adjusted free cash flow on average from fiscal 2024 to 2026.

Negatives

• Cardinal Health will not be renewing its pharmaceutical distribution contracts with OptumRx, which expire at the end of June 2024.
• The loss of the OptumRx contract, which accounted for 16% of fiscal 2023 revenue, will negatively impact the company's revenue.
• The company anticipates lower-than-average adjusted free cash flow in fiscal 2025 due to the unwinding of negative net working capital associated with the OptumRx contract.

Risks

• The nonrenewal of the OptumRx contract poses a risk to Cardinal Health's revenue and profitability.
• The company faces risks from ongoing inflationary pressures, which could impact its ability to achieve its financial targets.
• Competitive pressures in Cardinal Health's various lines of business could lead to reduced purchases or contract terminations by other customers.
• Uncertainties related to the pricing of branded pharmaceuticals and the performance of the generics program could also impact the company's financial results.
• The company is subject to risks and uncertainties described in its Form 10-K, Form 10-Q and Form 8-K reports.

Future Outlook

Cardinal Health expects growth in fiscal 2025 in both Pharmaceutical and Specialty Solutions segment profit and non-GAAP diluted EPS, partially offsetting the impact of the OptumRx contract loss. The company also anticipates generating approximately $2B in adjusted free cash flow on average from fiscal 2024 to 2026.

Management Comments

• We have plans in place to continue delivering profitable growth in fiscal 2025, and we are pleased to reaffirm our long-term targets for the Pharmaceutical and Specialty Solutions segment and enterprise, despite this nonrenewal, said Jason Hollar, CEO of Cardinal Health.
• We remain confident in the resiliency and strong value proposition of our business and look forward to updating you on our continued progress on our upcoming earnings call, said Jason Hollar, CEO of Cardinal Health.
• Our team remains focused on driving our strategy and executing on behalf of our customers, said Debbie Weitzman, CEO Pharmaceutical and Specialty Solutions.
• We are excited about the many other opportunities in the marketplace, such as the onboarding of new customers and the additional capabilities from the integration of Specialty Networks in fiscal 2025, said Debbie Weitzman, CEO Pharmaceutical and Specialty Solutions.

Industry Context

The loss of the OptumRx contract highlights the competitive nature of the pharmaceutical distribution industry and the importance of maintaining strong customer relationships. Cardinal Health's ability to offset this loss through new customer wins and specialty growth will be closely watched by investors and competitors.

Comparison to Industry Standards

• Cardinal Health's long-term EPS growth target of 12-14% is ambitious compared to some of its peers in the healthcare distribution sector, such as McKesson and AmerisourceBergen, which have historically shown more moderate growth.
• The loss of a major contract like OptumRx is a significant event, and the company's ability to maintain its financial targets will be a key indicator of its operational resilience compared to industry benchmarks.
• The company's focus on specialty solutions aligns with a broader industry trend towards higher-margin, specialized pharmaceutical distribution, which is also being pursued by competitors like AmerisourceBergen.

Stakeholder Impact

• Shareholders may experience some short-term uncertainty due to the loss of the OptumRx contract, but the reaffirmation of financial targets should provide some reassurance.
• Employees may be impacted by the shift in business strategy, but the company's focus on growth should provide opportunities.
• Customers may see changes in service offerings as Cardinal Health adjusts to the loss of the OptumRx contract.
• Suppliers may need to adjust their supply chains based on the changes in Cardinal Health's distribution network.
• Creditors will likely monitor the company's financial performance closely, particularly its cash flow.

Next Steps

• Cardinal Health will focus on onboarding new customers and integrating Specialty Networks in fiscal 2025.
• The company will provide updates on its progress during its upcoming earnings call.

Key Dates

Keywords

pharmaceutical distribution, OptumRx, contract nonrenewal, EPS guidance, long-term targets, revenue, free cash flow, specialty solutions, segment profit, healthcare